Beili Wu

Beili Wu

Auto-generated profile, based on publicly available information

Beili Wu

State Key Laboratory of Drug Research, State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2013 in Science
Verified
Journal Article
Closed access
PDF file
QTQiuxiang Tan
Qiuxiang Tan
YZYa Zhu
Ya Zhu
JLJian Li
Jian Li
ZCZhuxi Chen
Zhuxi Chen
GHGye Won Han
Gye Won Han
BWBeili Wu
Beili Wu
CCR5-Maraviroc Structure: The chemokine receptor CCR5, a G protein–coupled receptor best known as a co-receptor during HIV-1 infection, is important in a variety of physiological processes. Tan et al. (p. 1387 , published online 12 September; see the Perspective by Klasse ) now report the high-resolution crystal structure of CCR5 bound to the HIV-1 entry inhibitor, Maraviroc. The structure suggests that Maraviroc acts as a noncompetitive inhibitor by binding to a region of CCR5 that is distinct from the binding site of HIV-1 and chemokines. Comparison of the structure of CCR5 with the other HIV-1 co-receptor, the chemokine receptor CXCR4, provides insight into the co-receptor selectivity of the virus.

30 March 2015 in Nature
Verified
Journal Article
Closed access
PDF file
DZDandan Zhang
Dandan Zhang
ZGZhan-Guo Gao
Zhan-Guo Gao
KZKaihua Zhang
Kaihua Zhang
EKEvgeny Kiselev
Evgeny Kiselev
SCSteven Crane
Steven Crane
BWBeili Wu
Beili Wu

30 April 2014 in Nature
Verified
Journal Article
Open access
PDF file
JZJin Zhang
Jin Zhang
KZKaihua Zhang
Kaihua Zhang
ZGZhan-Guo Gao
Zhan-Guo Gao
SPSilvia Paoletta
Silvia Paoletta
DZDandan Zhang
Dandan Zhang
QZQiang Zhao
Qiang Zhao
An X-ray structure of human P2Y12 receptor, a clinical drug target for platelet aggregation inhibitors, is presented in complex with an agonist, providing insight into the δ-group of class A G-protein-coupled receptors. Two papers in this issue of Nature present the crystal structures of the human P2Y12 receptor, first in complex with the antithrombotic drug AZD1283, and second, bound to a full agonist (a close analogue of endogenous agonist ADP) and to a partial agonist. P2Y receptors are a family of purinergic G-protein-coupled receptors (GPCRs) that are activated by extracellular nucleotides. The P2Y12 receptor is found mainly on the surface of platelets, where it regulates platelet activation and thrombus formation, and it is the target of several important antithrombotic drugs. In overall structure, P2Y12 receptor is found to be similar to other GPCRs, although both the shape and location of the ligand-binding pocket are unusual. Comparisons of the three newly determined structures reveal that agonist binding induces a large-scale rearrangement of the extracellular domains of the GPCR. The P2Y12 receptor (P2Y12R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clinical drug targets for inhibition of platelet aggregation. Although mutagenesis and modelling studies of the P2Y12R provided useful insights into ligand binding1,2,3,4, the agonist and antagonist recognition and function at the P2Y12R remain poorly understood at the molecular level. Here we report the structures of the human P2Y12R in complex with the full agonist 2-methylthio-adenosine-5′-diphosphate (2MeSADP, a close analogue of endogenous agonist ADP) at 2.5 Å resolution, and the corresponding ATP derivative 2-methylthio-adenosine-5′-triphosphate (2MeSATP) at 3.1 Å resolution. These structures, together with the structure of the P2Y12R with antagonist ethyl 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283)5, reveal striking conformational changes between nucleotide and non-nucleotide ligand complexes in the extracellular regions. Further analysis of these changes provides insight into a distinct ligand binding landscape in the δ-group of class A G-protein-coupled receptors (GPCRs). Agonist and non-nucleotide antagonist adopt different orientations in the P2Y12R, with only partially overlapped binding pockets. The agonist-bound P2Y12R structure answers long-standing questions surrounding P2Y12R–agonist recognition, and reveals interactions with several residues that had not been reported to be involved in agonist binding. As a first example, to our knowledge, of a GPCR in which agonist access to the binding pocket requires large-scale rearrangements in the highly malleable extracellular region, the structural and docking studies will therefore provide invaluable insight into the pharmacology and mechanisms of action of agonists and different classes of antagonists for the P2Y12R and potentially for other closely related P2YRs.

20 March 2020 in Science
Verified
Journal Article
Closed access
PDF file
AQAnna Qiao
Anna Qiao
SHShuo Han
Shuo Han
XLXinmei Li
Xinmei Li
ZLZhixin Li
Zhixin Li
PZPeishen (Elva) Zhao
Peishen (Elva) Zhao
BWBeili Wu
Beili Wu
Choosing a partner that fits: G protein–coupled receptors (GPCRs) are responsible for transducing diverse signals from outside to inside cells. This process requires specificity both in ligand binding to GPCRs and in coupling between GPCRs and their intracellular partners, G proteins. Qiao et al. determined the structure of the human glucagon receptor (GCGR), a type B GPCR, bound to glucagon and one of two heterotrimeric G proteins, G s or G i1 . GCGR signals mainly through G s , and the structures provide a basis for this specificity. Conformational changes in GCGR, relative to the inactive state, create a binding cavity for the G proteins. The pocket is opened sufficiently to accommodate a bulky binding motif in G s . G i1 can still bind but the pocket does not close around it, so there is a smaller interaction interface. Science , this issue p. 1346

16 June 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SLShuling Lin
Shuling Lin
SHShuo Han
Shuo Han
XCXiaoqing Cai
Xiaoqing Cai
QTQiuxiang Tan
Qiuxiang Tan
KZKexiu Zhou
Kexiu Zhou
BWBeili Wu
Beili Wu

25 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FZFenghui Zhao
Fenghui Zhao
QZQingtong Zhou
Qingtong Zhou
ZCZhaotong Cong
Zhaotong Cong
KHKaini Hang
Kaini Hang
XZXinyu Zou
Xinyu Zou
MWMing-Wei Wang
Ming-Wei Wang
Glucose homeostasis, regulated by glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) is critical to human health. Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dual agonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their multiplexed pharmacological actions over monoagonists such as semaglutide, we determine cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR. The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the near-atomic level. Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy. Our findings provide valuable insights into the structural basis of functional versatility of tirzepatide and peptide 20.